

# Contents

<i>List of Contributors</i>	xvii
<i>Foreword</i>	xxiii
<i>María José Alonso</i>	
<i>Preface</i>	xxv
<i>Acknowledgments</i>	xxvii
<b>Part One General Aspects of Chitosan</b>	<b>1</b>
<b>1 Chemical and Technological Advances in Chitins and Chitosans Useful for the Formulation of Biopharmaceuticals</b>	<b>3</b>
<i>Riccardo A. A. Muzzarelli</i>	
1.1 Introduction	3
1.2 Safety of Chitins and Chitosans	4
1.3 Ionic Liquids: New Solvents and Reaction Media	5
1.4 Chitin and Chitosan Nanofibrils	8
1.4.1 Mechanically Isolated Nanofibrils in the Presence of Acetic Acid	8
1.4.2 Nanochitosan Obtained from Partially Deacetylated Chitin or Deacetylated Nanochitin	9
1.5 Electrospun Nanofibers	10
1.6 Polyelectrolyte Complexes and Mucoadhesion	12
1.6.1 Chitosan Polyelectrolyte Complexes Soluble in Alkaline Medium	14
1.6.2 Polyelectrolyte Complexes of Regioselectively Oxidized Chitin	15
1.6.3 Polyelectrolyte Complexes of Chitosan with Bacterial Cell Wall Components	15
1.7 Conclusions and Future Perspectives	16
Acknowledgments	16
References	16
<b>2 Physical Properties of Chitosan and Derivatives in Sol and Gel States</b>	<b>23</b>
<i>Marguerite Rinaudo</i>	
2.1 Introduction	23
2.2 Chitin	24
2.2.1 Solid State of Chitin	24
2.2.2 Solubility of Chitin	24
2.2.3 Characterization of Chitin	26
2.2.4 Processing of Chitin Solution and Physical Properties of Materials	28
2.3 Chitosan	28
2.3.1 Solubility of Chitosan	28
2.3.2 Characterization of Chitosan	29

2.3.3	Processing of Chitosan-Based Materials	31
2.3.4	Complex Materials Based on Interacting Chitosan and Chitosan Derivatives	31
2.4	Conclusions and Future Perspectives	36
	References	36
<b>3</b>	<b>Absorption Promotion Properties of Chitosan and Derivatives</b>	<b>45</b>
	<i>Akira Yamamoto</i>	
3.1	Introduction	45
3.2	Effect of Chitosan on the Intestinal Absorption of Poorly Absorbable Drugs	47
3.3	Effect of Chitosan Derivatives on the Intestinal Absorption of Poorly Absorbable Drugs	47
3.4	Effect of Chitosan Oligomers on the Intestinal Absorption of Poorly Absorbable Drugs	48
3.5	Colon-Specific Delivery of Insulin Using Chitosan Capsules	51
3.6	Conclusions and Future Perspectives	54
	References	54
<b>4</b>	<b>Biocompatibility and Biodegradation of Chitosan and Derivatives</b>	<b>57</b>
	<i>Ahmad Sukari Halim, Lim Chin Keong, Ismail Zainol, and Ahmad Hazri Abdul Rashid</i>	
4.1	Introduction	57
4.2	Biocompatibility Evaluation of Chitosan and Derivatives	58
4.2.1	<i>In Vitro</i> Biocompatibility	60
4.2.2	<i>In Vivo</i> Biocompatibility	63
4.2.3	Effect of Sterilization on Biocompatibility	64
4.3	Biodegradation of Chitosan and Derivatives	65
4.3.1	Factors Influencing the Biodegradation of Chitosan and Derivatives	67
4.3.2	<i>In Vitro</i> Biodegradation of Chitosan and Derivatives	68
4.3.3	<i>In Vivo</i> Biodegradation of Chitosan and Derivatives	69
4.4	Conclusions and Future Perspectives	69
	References	70
<b>5</b>	<b>Biological and Pharmacological Activity of Chitosan and Derivatives</b>	<b>75</b>
	<i>Teresa Cunha, Branca Teixeira, Bárbara Santos, Marlene Almeida, Gustavo Dias, and José das Neves</i>	
5.1	Introduction	75
5.2	Biological Activity	76
5.2.1	Antimicrobial Activity	76
5.2.2	Immune Effects and Anti-Inflammatory Activity	77
5.2.3	Antioxidant Activity	78
5.2.4	Anticancer Activity	79
5.2.5	Blood Coagulation Effects	79
5.2.6	Antidiabetic Activity	80
5.2.7	Neuroprotective Activity	80
5.2.8	Other Biological Activities	81
5.3	Chitosan's Usefulness in Therapy and Alternative Medicine	82
5.3.1	Wound Healing	82
5.3.2	Obesity	82

5.3.3	Dyslipidemia	83
5.3.4	Dental Plaque	83
5.3.5	Renal Failure	83
5.3.6	Other Uses	84
5.4	Conclusions and Future Perspectives	84
	Acknowledgments	85
	References	85
	Further Reading	92
<b>6</b>	<b>Biological, Chemical, and Physical Compatibility of Chitosan and Biopharmaceuticals</b>	<b>93</b>
	<i>Masayuki Ishihara, Masanori Fujita, Satoko Kishimoto, Hidemi Hattori, and Yasuhiro Kanatani</i>	
6.1	Introduction	93
6.2	Structural Features of Chitosan and Its Derivatives	94
6.3	Biocompatibility for Chitosan and Its Derivatives	95
6.3.1	Inflammatory Reaction	95
6.3.2	Foreign Body Reaction	96
6.3.3	Biocompatibility Testing	97
6.4	Biocompatibility of Photo-Cross-Linkable Chitosan Hydrogel	98
6.4.1	Photo-Cross-Linkable Chitosan Hydrogel	98
6.4.2	Photo-Cross-Linkable Chitosan Hydrogel as a Biological Adhesive	99
6.4.3	Photo-Cross-Linkable Chitosan Hydrogel as a Wound Dressing	99
6.4.4	Safety of Photo-Cross-Linkable Chitosan Hydrogel	99
6.5	Physical and Chemical Compatibility of Chitosan and Its Derivatives	100
6.5.1	Chitosan-Based Peptide and Protein Delivery Systems	101
6.5.2	Chitosan-Based Gene Delivery Systems	101
6.5.3	Physicochemical Characterization of Protein-, Peptide-, or Gene-Loaded Chitosan-Based PECs	101
6.6	Conclusions and Future Perspectives	102
	References	103
<b>7</b>	<b>Approaches for Functional Modification or Cross-Linking of Chitosan</b>	<b>107</b>
	<i>A. Anitha, N. Sanoj Rejinold, Joel D. Bumgardner, Shanti V. Nair, and Rangasamy Jayakumar</i>	
7.1	Introduction	107
7.2	General Awareness of Chitosan Cross-Linking Methods	108
7.2.1	Chemical Cross-Linking	108
7.2.2	Radiation Cross-Linking	111
7.2.3	Physical Cross-Linking	111
7.3	Modified Chitosan: Synthesis and Characterization	112
7.3.1	Synthesis of Water-soluble Chitosan Derivatives	112
7.3.2	Thiolation	113
7.3.3	Succinylation	113
7.3.4	Chitosan-Grafted Polymers	115
7.4	Applications of Modified Chitosan and Its Derivatives in Drug Delivery	118
7.5	Conclusions and Future Perspectives	118
	Acknowledgments	118
	References	119

<b>Part Two Biopharmaceuticals Formulation and Delivery Aspects Using Chitosan and Derivatives</b>	<b>125</b>
<b>8 Use of Chitosan and Derivatives in Conventional Biopharmaceutical Dosage Forms Formulation</b>	<b>127</b>
<i>Teófilo Vasconcelos, Pedro Barrocas, and Rui Cerdeira</i>	
8.1 Introduction	127
8.2 Advantageous Properties of Chitosan and Its Derivatives	128
8.3 Oral Administration	129
8.4 Buccal Administration	131
8.5 Nasal Administration	132
8.6 Pulmonary Administration	132
8.7 Transdermal Administration	133
8.8 Conclusions and Future Perspectives	133
References	134
<b>9 Manufacture Techniques of Chitosan-Based Microparticles and Nanoparticles for Biopharmaceuticals</b>	<b>137</b>
<i>Franca Ferrari, M. Cristina Bonferoni, Silvia Rossi, Giuseppina Sandri, and Carla M. Caramella</i>	
9.1 Introduction	137
9.2 Water-in-Oil Emulsion and Chemical Cross-linking	138
9.3 Drying Techniques	141
9.3.1 Spray Drying	141
9.3.2 Supercritical Fluid Drying	142
9.3.3 Electrospraying	143
9.4 Ionic Cross-linking Methods	144
9.4.1 Low-MW Molecules	145
9.4.2 Macromolecules	148
9.5 Coacervation and Precipitation Method	151
9.6 Direct Interaction between Chitosan and Biopharmaceuticals	152
9.6.1 DNA–Chitosan Interaction	152
9.6.2 siRNA–Chitosan Interaction	153
9.7 Conclusions and Future Perspectives	153
References	154
<b>10 Chitosan and Derivatives for Biopharmaceutical Use: Mucoadhesive Properties</b>	<b>159</b>
<i>Katharina Leithner and Andreas Bernkop-Schnürch</i>	
10.1 Introduction	159
10.2 Mucoadhesion	160
10.2.1 The Mucus	160
10.2.2 The Interaction of Mucoadhesives and Mucosa	160
10.2.3 Mucoadhesion	160
10.2.4 Chitosan as a Mucoadhesive Polymer	161
10.3 Chitosan and Its Derivatives	161

10.3.1	Overview	161
10.3.2	Thiolated Chitosan	161
10.3.3	Chitosan–EDTA and Chitosan–DTPA	164
10.3.4	Trimethyl Chitosan	167
10.3.5	Mono- <i>N</i> -Carboxymethyl Chitosan	168
10.3.6	<i>N</i> -Sulfonato- <i>N,O</i> -Carboxymethylchitosan	168
10.3.7	Hydrophobically Modified Chitosans	169
10.3.8	PEGylated Chitosan	170
10.3.9	Chitosan–Succinate and Chitosan–Phthalate	170
10.4	Biopharmaceutical Use of Chitosan and Its Derivatives	171
10.4.1	Overview	171
10.4.2	Oral Drug Delivery	171
10.4.3	Nasal Drug Delivery	174
10.4.4	Buccal Drug Delivery	175
10.5	Conclusions and Future Perspectives	175
	References	176
<b>11</b>	<b>Chitosan-Based Systems for Mucosal Delivery of Biopharmaceuticals</b>	<b>181</b>
	<i>Sonia Al-Qadi, Ana Grenha, and Carmen Remuñán-López</i>	
11.1	Introduction	181
11.2	Important Challenges for the Delivery of Biopharmaceuticals by Mucosal Routes	182
11.3	Interest in Chitosan for Mucosal Delivery of Biopharmaceuticals	184
11.3.1	Chitosan Physicochemical Properties	184
11.3.2	Biological Properties of Chitosan	185
11.3.3	Mucoadhesive and Permeation-Enhancing Properties	186
11.3.4	Chitosan Derivatives	187
11.4	Chitosan-Based Delivery Nanosystems for Mucosal Delivery of Biopharmaceuticals	188
11.4.1	Oral Delivery of Biopharmaceuticals	189
11.4.2	Nasal Delivery of Biopharmaceuticals	192
11.4.3	Pulmonary Delivery of Biopharmaceuticals	195
11.5	Conclusions and Future Perspectives	200
	Acknowledgments	200
	References	201
<b>12</b>	<b>Chitosan-Based Delivery Systems for Mucosal Vaccination</b>	<b>211</b>
	<i>Gerrit Borchard, Farnaz Esmaeili, and Simon Heuking</i>	
12.1	Introduction	211
12.2	Adjuvant Properties of Chitosan	212
12.3	Chitosan in the Delivery of Protein and Subunit Vaccines	213
12.4	Chitosan-Based Formulations of DNA Vaccines	215
12.5	Vaccine Formulations Using Chitosan in Combination with Other Polymers	216
12.6	Chitosan Derivatives in Vaccine Carrier Design	217
12.6.1	<i>N,N,N</i> -Trimethyl Chitosan	217
12.6.2	Nasal Delivery of TMC-Based Vaccine Formulations	218
12.6.3	Pulmonary Delivery of TMC-Based Vaccine Formulations	219

12.6.4	Oral Delivery of TMC-Based Vaccine Formulations	219
12.6.5	Other Chitosan Derivatives	219
12.7	Conclusions and Future Perspectives	220
	References	220
<b>13</b>	<b>Chitosan-Based Nanoparticulates for Oral Delivery of Biopharmaceuticals</b>	<b>225</b>
	<i>Filipa Antunes, Fernanda Andrade, and Bruno Sarmento</i>	
13.1	Introduction	225
13.2	Challenges on the Oral Delivery of Therapeutic Proteins	226
13.3	Challenges on the Oral Delivery of Genetic Material	227
13.4	Role of Chitosan in the Protection of Biopharmaceuticals in the Gastrointestinal Tract	229
13.5	Chitosan-Based Nanoparticles for Oral Delivery of Therapeutic Proteins	232
13.6	Chitosan-Based Nanoparticles for Oral Delivery of Genetic Material	234
13.7	Conclusions and Future Perspectives	236
	Acknowledgments	237
	References	237
<b>14</b>	<b>Chitosan-Based Systems for Ocular Delivery of Biopharmaceuticals</b>	<b>243</b>
	<i>Suresh P. Vyas, Rishi Paliwal, and Shivani Rai Paliwal</i>	
14.1	Introduction	243
14.2	Ocular Delivery of Biopharmaceuticals	244
14.3	Chitosan: A Suitable Biomaterial for Ocular Therapeutics	244
14.4	Chitosan-Based Systems for Ocular Delivery of Biomacromolecules	245
14.4.1	Chitosan Solutions as Permeation Enhancers	245
14.4.2	Chitosan-Based Nanoemulsions	246
14.4.3	Chitosan Micro- and Nanoparticles	247
14.4.4	Chitosan-Coated Delivery Systems	248
14.4.5	Chitosan Complexed with Other Biomaterials	248
14.5	Toxicological and Compatibility Aspects of Chitosan-Based Ocular Systems	249
14.6	Conclusions and Future Perspectives	250
	References	250
<b>15</b>	<b>Chemical Modification of Chitosan for Delivery of DNA and siRNA</b>	<b>255</b>
	<i>You-Kyoung Kim, Hu-Lin Jiang, Ding-Ding Guo, Yun-Jaie Choi, Myung-Haing Cho, Toshihiro Akaike, and Chong-Su Cho</i>	
15.1	Introduction	255
15.2	Hydrophilic Modification	256
15.3	Hydrophobic Modification	257
15.4	Specific Ligand Modification	259
15.4.1	Galactose Ligand	259
15.4.2	Mannose Ligand	261
15.4.3	Folate Ligand	263
15.5	pH-Sensitive Modification	264
15.5.1	Imidazole	264
15.5.2	PEI	267
15.5.3	Spermine	269

15.5.4	PAMAM Dendron	269
15.6	Conclusions and Future Perspectives	269
	Acknowledgment	269
	References	269
<b>Part Three</b>	<b>Advanced Application of Chitosan and Derivatives for Biopharmaceuticals</b>	<b>275</b>
<b>16</b>	<b>Target-Specific Chitosan-Based Nanoparticle Systems for Nucleic Acid Delivery</b>	<b>277</b>
	<i>Shardool Jain and Mansoor Amiji</i>	
16.1	Introduction	277
16.1.1	Nanotechnology in Vaccine and Drug Delivery	277
16.1.2	Chitosan: A Versatile Biopolymer	278
16.1.3	Chitosan for Delivery of Nucleic Acid Vaccines and Therapies	279
16.1.4	Passive versus Active Systemic Targeted Delivery	280
16.2	Chitosan-Based Nanoparticle Delivery Systems	283
16.2.1	Chitosan-Based Nanodelivery Systems for DNA Vaccines	283
16.2.2	Chitosan-Based Nanodelivery Systems for Nucleic Acid Therapy	285
16.3	Illustrative Examples of DNA Vaccine Delivery	286
16.3.1	Mucosal Vaccination	286
16.3.2	Systemic Vaccination	287
16.4	Illustrative Examples of Nucleic Acid Delivery Systems for Cancer Therapy	288
16.5	Illustrative Examples of Nucleic Acid Delivery Systems for Anti-Inflammatory Therapy	291
16.6	Conclusions and Future Perspectives	294
	References	295
<b>17</b>	<b>Functional PEGylated Chitosan Systems for Biopharmaceuticals</b>	<b>301</b>
	<i>Hee-Jeong Cho, Goen Kim, Hyeok-Seung Kwon, and Yu-Kyoung Oh</i>	
17.1	Introduction	301
17.1.1	Physicochemical Properties of PEGylated Chitosan	302
17.1.2	Biological Properties of PEGylated Chitosan	303
17.2	PEGylated Chitosan for the Delivery of Proteins and Peptides	304
17.2.1	Protein Delivery	304
17.2.2	Peptide Delivery	307
17.3	PEGylated Chitosan for Delivery of Nucleic Acids	308
17.3.1	Plasmid DNA Delivery	308
17.3.2	Oligonucleotide Delivery	310
17.4	PEGylated Chitosan for Delivery of Other Macromolecular Biopharmaceuticals	311
17.5	PEGylated Chitosan Used for Cellular Scaffolds	313
17.6	Conclusions and Future Perspectives	313
	References	314
<b>18</b>	<b>Stimuli-Sensitive Chitosan-Based Systems for Biopharmaceuticals</b>	<b>319</b>
	<i>Cuiping Zhai, Jinfang Yuan, and Qingyu Gao</i>	
18.1	Introduction	319
18.2	pH-Sensitive Chitosan-Based Systems	319

18.3	Thermosensitive Chitosan-Based Systems	321
18.4	pH-Sensitive and Thermosensitive Chitosan-Based Systems	323
18.5	pH- and Ionic-Sensitive Chitosan-Based Systems	325
18.6	Photo-Sensitive Chitosan-Based Systems	325
18.7	Electrical-Sensitive Chitosan-Based Systems	326
18.8	Magnetic-Sensitive Chitosan-Based Systems	326
18.9	Chemical Substance-Sensitive Chitosan-Based Systems	327
18.10	Conclusions and Future Perspectives	327
	References	328
<b>19</b>	<b>Chitosan Copolymers for Biopharmaceuticals</b>	<b>333</b>
	<i>Ramon Novoa-Carballal, Ricardo Riguera, and Eduardo Fernandez-Megia</i>	
19.1	Introduction	333
19.1.1	General Copolymerization Methods	334
19.1.2	Chitosan Copolymers for Biopharmaceuticals	336
19.1.3	The Integrity of the Chitosan Chain in Chitosan Copolymers	336
19.2	Chitosan-g-Poly(Ethylene Glycol)	337
19.2.1	Synthetic Procedures towards the Preparation of Chitosan-g-Poly(Ethylene Glycol)	337
19.2.2	Applications of Chitosan-g-Poly(Ethylene Glycol) with Biopharmaceuticals	347
19.3	Chitosan-g-Polyethylenimine	347
19.3.1	Synthetic Strategies toward the Preparation of Chitosan-g-Polyethylenimine	350
19.3.2	Applications to Gene Therapy	353
19.4	Other Copolymers of Chitosan	357
19.4.1	Chitosan-g-Polypeptide	357
19.4.2	Grafting of Chitosan to Thermoresponsive Polymers	357
19.4.3	Chitosan-g-Methacrylates	362
19.5	Copolymers of Chitosan with Promising Applications	363
19.5.1	Chitosan-g-Polyesters	363
19.5.2	Chitosan-g-Polysaccharides	366
19.5.3	Block Copolymers of Chitosan	367
19.5.4	Chitosan-g-Dendrimer	368
19.6	Conclusions and Future Perspectives	368
	References	369
<b>20</b>	<b>Application of Chitosan for Anticancer Biopharmaceutical Delivery</b>	<b>381</b>
	<i>Claudia Philippi, Brigitta Loretz, Ulrich F. Schaefer, and Claus-Michael Lehr</i>	
20.1	Introduction	381
20.2	Chitosan and Cancer: Intrinsic Antitumor Activity of the Polymer Itself	382
20.2.1	Effects of Chitosan, Low-Molecular Weight Chitosan, and Chitooligosaccharides	382
20.2.2	Effects of Chitosan Nanoparticles	383
20.3	Chitosan Formulations Developed for Classic Anticancer Drugs	383
20.3.1	Chemically Modified Chitosans or Chitosan-Drug Conjugates	383
20.3.2	Nanoparticulate Carrier Systems	384
20.3.3	Chitosans as Absorption Enhancers	384



20.4	Biopharmaceuticals Delivered by Chitosan Preparations	384
20.4.1	Nucleic Acid–Based Therapeutics	385
20.4.2	Peptide-Based Actives for Cancer Treatment	387
20.5	Active Targeting Strategies and Multifunctional Chitosan Formulations	388
20.5.1	Active Targeting Strategies	388
20.5.2	Multifunctional Chitosan Nanoparticles	389
20.6	Conclusions and Future Perspectives	389
	References	390
<b>21</b>	<b>Chitosan-Based Biopharmaceutical Scaffolds in Tissue Engineering and Regenerative Medicine</b>	<b>393</b>
	<i>Tao Jiang, Meng Deng, Wafa I. Abdel- Fattah, and Cato T. Laurencin</i>	
21.1	Introduction	393
21.2	Fabrication of Chitosan-Based Biopharmaceuticals Scaffolds	395
21.2.1	Techniques for Fabricating Chitosan-Based Scaffolds	395
21.2.2	Functionalization of Chitosan-Based Scaffolds via Biopharmaceuticals	402
21.3	Applications of Chitosan-Based Biopharmaceutical Scaffolds in Tissue Engineering and Regenerative Medicine	403
21.3.1	Regeneration of Soft Tissue	404
21.3.2	Regeneration of Hard Tissue	410
21.4	Future Trends: Regenerative Engineering	416
21.5	Conclusions and Future Perspectives	417
	Acknowledgments	417
	References	418
<b>22</b>	<b>Wound-Healing Properties of Chitosan and Its Use in Wound Dressing Biopharmaceuticals</b>	<b>429</b>
	<i>Tyler G. St. Denis, Tianhong Dai, Ying-Ying Huang, and Michael R. Hamblin</i>	
22.1	Introduction	429
22.2	Brief Review of Wound Repair	430
22.2.1	Inflammatory Phase	430
22.2.2	Proliferative Phase	431
22.2.3	Remodeling Phase	432
22.3	Wound-Healing Effects of Chitosan	433
22.3.1	<i>In Vitro</i> Studies	433
22.3.2	<i>In Vivo</i> Studies	435
22.3.3	Clinical Studies	438
22.4	Chitosan for Wound Therapeutics Delivery	440
22.4.1	Antimicrobials	440
22.4.2	Combination with Photodynamic Therapy	442
22.4.3	Growth Factors	443
22.4.4	Delivery of Other Drugs	444
22.5	Conclusions and Future Perspectives	444
	Acknowledgments	447
	References	447

<b>Part Four</b>	<b>Regulatory Status, Toxicological Issues, and Clinical Perspectives</b>	<b>451</b>
<b>23</b>	<b>Toxicological Properties of Chitosan and Derivatives for Biopharmaceutical Applications</b>	<b>453</b>
	<i>Thomas J. Kean and Maya Thanou</i>	
23.1	Introduction	453
23.2	<i>In Vitro</i> Toxicity of Chitosan and Derivatives	454
23.2.1	<i>In Vitro</i> Toxicity of Chitosan	454
23.2.2	<i>In Vitro</i> Toxicity of Chitosan Derivatives	455
23.2.3	<i>In Vitro</i> Toxicity of Chitosan Formulations	455
23.2.4	Antibacterial, Antifungal, and Antiparasitic Activities of Chitosan and Chitosan Derivatives	457
23.3	<i>In Vivo</i> Toxicity of Chitosan and Derivatives	457
23.3.1	<i>In Vivo</i> Toxicity of Chitosan	457
23.3.2	<i>In Vivo</i> Toxicity of Chitosan Derivatives	458
23.3.3	<i>In Vivo</i> Toxicity of Chitosan Formulations	458
23.4	Conclusions and Future Perspectives	459
	References	459
<b>24</b>	<b>Regulatory Status of Chitosan and Derivatives</b>	<b>463</b>
	<i>Michael Dornish, David S. Kaplan, and Sambasiva R. Arepalli</i>	
24.1	Introduction	463
24.2	Source	464
24.3	Characterization	464
24.4	Purity	465
24.4.1	Impurities	465
24.4.2	Heavy Metals	465
24.4.3	Protein	465
24.4.4	Microbiological Bioburden	466
24.4.5	Bacterial Endotoxin	466
24.5	Applications of Advanced Uses of Chitosan	466
24.5.1	Tissue Engineering	466
24.5.2	Gene Delivery with Chitosan	467
24.5.3	Nasal Drug and Vaccine Delivery	467
24.6	Regulatory Considerations for Chitosan and Chitosan Derivatives in the European Union, and Medical Devices or Combination Products with Medical Device (CDRH) Lead	468
24.6.1	The US Food and Drug Administration	468
24.7	Regulatory Pathways	469
24.8	Chitosan Medical Products: US Regulatory Review Processes for Medical Devices or Combination Products with CDRH Lead	469
24.9	Chitosan Wound Dressings	470
24.9.1	Hemostasis and Antimicrobial Activities	470
24.10	The European Regulatory System: The European Medicines Agency (EMA) and European Directorate for the Quality of Medicines (EDQM)	474
24.10.1	Pharmaceuticals – Europe	474
24.10.2	Medical Devices – Europe	475

24.11	Further Regulatory Considerations	475
24.11.1	Generally Recognized as Safe (GRAS)	476
24.11.2	Pharmacopoeia Monographs	476
24.11.3	Standards Development Organizations	476
24.12	Conclusions and Future Perspectives	477
	Acknowledgments	478
24.13	Disclaimer	478
	References	478
<b>25</b>	<b>Patentability and Intellectual Property Issues Related to Chitosan-Based Biopharmaceutical Products</b>	<b>483</b>
	<i>Mafalda Videira and Rogério Gaspar</i>	
25.1	Introduction	483
25.2	Setting the Scene: The Role of Chitosan as a Pharmaceutical Excipient	484
25.2.1	Current Achievements in Chitosan Use	484
25.2.2	Chitosan-Based Ocular Therapy	486
25.2.3	Tissue Engineering and Wound Management	487
25.2.4	Drug Delivery Systems: Emerging Targeting Solutions	488
25.2.5	Recent Trends in Using Chitosan	494
25.3	Addressing the Drivers for Scientific Progress on Chitosan: Innovation and Inventability	495
25.3.1	Is There a Next Generation of Chitosan?	495
25.4	Conclusions and Future Perspectives	496
	References	497
<b>26</b>	<b>Quality Control and Good Manufacturing Practice (GMP) for Chitosan-Based Biopharmaceutical Products</b>	<b>503</b>
	<i>Torsten Richter, Maika Gulich, and Katja Richter</i>	
	List of Abbreviations	503
26.1	Introduction	504
26.2	Regulatory Requirements for Production	505
26.2.1	Medical Devices	505
26.2.2	Excipients	506
26.2.3	APIs/Pharmaceuticals	507
26.3	Manufacturing GMP: Fundamental Considerations	508
26.4	Requirements for Rooms, Personnel, and Equipment	511
26.5	Qualification and Validation	511
26.5.1	Qualification	511
26.5.2	Process Validation	513
26.6	Quality Control	513
26.6.1	Specific Features of Chitosan Quality Control	516
26.7	Monitoring and Maintenance of a GMP System	519
26.7.1	Vendor and Customer Audits	519
26.7.2	Public Authority Inspections	521
26.8	Conclusions and Future Perspectives	522
	References	522

<b>27</b>	<b>Preclinical and Clinical Use of Chitosan and Derivatives for Biopharmaceuticals: From Preclinical Research to the Bedside</b>	<b>525</b>
	<i>David A. Zaharoff, Michael Heffernan, Jonathan Fallon, and John W. Greiner</i>	
27.1	Introduction	525
27.2	Chitosan as a Parenteral (Subcutaneous) Vaccine Platform	526
27.2.1	Enhancement of Humoral and Cell-Mediated Immune Responses	526
27.2.2	Enhancement of the Immunoadjuvant Properties of GM-CSF	527
27.3	Chitosan as an Immunotherapeutic Platform	530
27.3.1	Intratumoral Immunotherapy with Chitosan–IL-12	530
27.3.2	Intravesical Immunotherapy of Superficial Bladder Carcinoma with Chitosan–IL-12	535
27.4	Conclusions and Future Perspectives	537
	References	539
	<b><i>Index</i></b>	<b>543</b>